Quantum Biopharma Stock (QNTM) Sees Retail Following Skyrocket Over 2,500% In A Week

Quantum BioPharma (QNTM), formerly FSD Pharma Inc. (HUGE), has seen a surge in retail investor interest over the past week while notching gains of over 7%.

Earlier this month, FSD Pharma underwent a significant transformation. The company consolidated its shares to increase the price to $18 per share and meet Nasdaq listing requirements. It was also rebranded as Quantum BioPharma (QNTM).

Quantum also conducted a private placement, offering new shares to existing Class A shareholders. This move aimed to restore voting rights to the Class A shares, aligning them closer to their pre-2018 public offering levels.

Adding to the recent buzz is the company's investment in Celly Nutrition, specifically their "unbuzzd" product — a drink designed to accelerate metabolism and aid in faster recovery from alcohol consumption.

It's set to launch as powder packs on Amazon later this month, with ready-to-drink versions planned for later in the year.

To support the release of unbuzzd, FSD Pharma launched a round of financing via the sale of 6,833,332 shares of HUGE stock at $203,469. The company has the option to sell more shares to raise additional funds.

Several retail investors on Stocktwits were talking about unbuzzd, with some users sharing screenshots of the product available for purchase on Amazon on Monday.

This coincided with a surge in trading volume of QNTM, exceeding double its daily average of about 24,000 shares.

However, the Amazon product link for unbuzzd on its official site currently leads to a "not found" page.

Currently, retail sentiment on Stocktwits for QNTM has turned 'neutral' (45/100) from 'bearish' a week ago. 

Read Next: Xpeng Stock Jumps, Retail Turns ‘Bullish’ After CEO Boosts Stake